No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Trump Says 'Major Tariff on Pharmaceuticals' Coming Soon
Benchmark Co. Maintains Biofrontera(BFRI.US) With Buy Rating, Maintains Target Price $7
Biofrontera's Growth Potential: Buy Rating Backed by FDA Approval and Positive Phase 3 Results
Biofrontera Shares Are Trading Lower After the Company Reported a FY24 Revenue Miss.
Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript Summary
Biofrontera Outlines 2025 Growth Strategies With New FDA Approvals and Clinical Progress